VetStem Biopharma CEO and Founder, Dr. Bob Harman, Interviewed in New Book “Stem Cell Therapy: A Rising Tide”

From the beginning we decided to be data driven, trying to get peer reviewed trials before we make recommendations.

VetStem Biopharma’s CEO and founder, Dr. Bob Harman DVM, MPVM, is featured in an interview with Dr. Neil H. Riordan PA, PhD in Riordan’s new book “Stem Cell Therapy: A Rising Tide”. Dr. Harman and Dr. Riordan met in 2003 and have remained in contact over the past 14 years. They bonded over an interest in the potential of stem cell therapy and a fast friendship was formed.

Dr. Harman has been a leader in this area for over a decade and has presented at dozens of human regenerative medicine conferences. He pulls from his biotechnology and veterinary experience to perfect the clinical application of stem cell therapy for various types of injuries, illnesses, and other healing-promoting applications. VetStem is leading in the development of regenerative medicine in the veterinary field, with over 13,000 animals treated in the last 13 years. Dr. Harman has also authored 13 peer-reviewed articles and book chapters.

The book, its full title, “Stem Cell Therapy: A Rising Tide, How Stem Cells Are Disrupting Medicine and Transforming Lives”, is an easy-to-read guide to all things stem cells. Dr. Riordan summarizes the science behind stem cell therapy in a language that is easy for anyone to understand. The science is combined with a collection of stories from actual patients treated with stem cells, making this book enjoyable for everyone.

On pages 120-133, Dr. Riordan interviews longtime friend and fellow stem cell enthusiast, Dr. Bob Harman. Though Dr. Riordan works in human medicine, these friends find many commonalities between human and veterinary medicine and the use of regenerative stem cell therapy. Dr. Harman gives a brief history of how VetStem Biopharma has evolved stating, “When we first looked at the technology, I thought that using these kinds of cells therapeutically would change everything about the dogma surrounding treatment of chronic and acute disease.” He went on to say, “From day one, we determined that we eventually needed an off-the-shelf product in order for the treatment to be affordable.” The two discuss VetStem’s continued contact with the FDA, intent to release an…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *